[
  {
    "ts": null,
    "headline": "Josh Brown on Pfizer (PFE): ‘I Was Dead Wrong, There’s No Turnaround’",
    "summary": "Pfizer Inc (NYSE:PFE) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Josh Brown, CEO of Ritholtz Wealth Management, explained in a recent program on CNBC why he’s bearish on Pfizer. Brown said he was “dead wrong” in hoping to see a turnaround at the pharma giant. “Do you know […]",
    "url": "https://finnhub.io/api/news?id=f45d015345c5e70a2b9e82c7a1b654da6f0cdae86e240ebab57423d3ad700534",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733453,
      "headline": "Josh Brown on Pfizer (PFE): ‘I Was Dead Wrong, There’s No Turnaround’",
      "id": 136113500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc (NYSE:PFE) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Josh Brown, CEO of Ritholtz Wealth Management, explained in a recent program on CNBC why he’s bearish on Pfizer. Brown said he was “dead wrong” in hoping to see a turnaround at the pharma giant. “Do you know […]",
      "url": "https://finnhub.io/api/news?id=f45d015345c5e70a2b9e82c7a1b654da6f0cdae86e240ebab57423d3ad700534"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=78ce4374cd4265fc195b8694418adc77c98a88b9b21eca962881f3e8f40cb523",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720620,
      "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "id": 136135768,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=78ce4374cd4265fc195b8694418adc77c98a88b9b21eca962881f3e8f40cb523"
    }
  },
  {
    "ts": null,
    "headline": "Ireland's 'economic miracle' at risk from tariffs",
    "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
    "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753719141,
      "headline": "Ireland's 'economic miracle' at risk from tariffs",
      "id": 136107800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
      "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed"
    }
  },
  {
    "ts": null,
    "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
    "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
    "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753714860,
      "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
      "id": 136108007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
      "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?",
    "summary": "BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=f70830f8cbd0141f6de70ea7c499261c59c4cf161be34563520c0b3eb9b4e37c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753709280,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?",
      "id": 136108346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=f70830f8cbd0141f6de70ea7c499261c59c4cf161be34563520c0b3eb9b4e37c"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "3 Surprisingly Underrated Stocks to Buy Right Now",
    "summary": "These big pharma stocks arguably aren't receiving the respect they deserve.",
    "url": "https://finnhub.io/api/news?id=2c18cb1b8ebe9da6cde6ba07872a248209a27dcaf7dd2002bf551202ec5842f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753699320,
      "headline": "3 Surprisingly Underrated Stocks to Buy Right Now",
      "id": 136108175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These big pharma stocks arguably aren't receiving the respect they deserve.",
      "url": "https://finnhub.io/api/news?id=2c18cb1b8ebe9da6cde6ba07872a248209a27dcaf7dd2002bf551202ec5842f2"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains a Hold on Pfizer (PFE)",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the top low volatility healthcare stocks to buy now. On July 22, Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $32.00. One of the primary factors behind this cautious rating is the impending patent expiration for Pfizer’s Tafamidis, […]",
    "url": "https://finnhub.io/api/news?id=6ec1514e2e01e37457f3ee7bb8d6ba419df0c974a8c4bf2b05231c7bd10b934c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682886,
      "headline": "Morgan Stanley Maintains a Hold on Pfizer (PFE)",
      "id": 136108348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the top low volatility healthcare stocks to buy now. On July 22, Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a price target of $32.00. One of the primary factors behind this cautious rating is the impending patent expiration for Pfizer’s Tafamidis, […]",
      "url": "https://finnhub.io/api/news?id=6ec1514e2e01e37457f3ee7bb8d6ba419df0c974a8c4bf2b05231c7bd10b934c"
    }
  }
]